Q-omics provides the consensus-scored MIR155HG profile across patient tissues and cancer cell-line models. MIR155HG expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR155HG is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, MIR155HG RNA expression shows 15,600 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where MIR155HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR155HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR155HG survival associations across molecular data types. MIR155HG RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR155HG RNA expression–survival associations across cancer types. High MIR155HG expression shows unfavorable associations in UVM, KIRC, KIRP and LGG, but favorable associations in SKCM and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR155HG RNA expression.
This table summarizes MIR155HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR155HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR155HG shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, STAD, BRCA and LIHC. The KIRC box plot shows higher MIR155HG RNA expression in tumor versus normal tissue (log2 FC = +1.747, t-test p < 0.001).
This table shows molecular features associated with MIR155HG in patient tissues and cancer cell lines. In patient samples, MIR155HG shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
